{"id":"tacrolimus-with-rapid-steroid-withdrawal","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity / renal dysfunction"},{"rate":null,"effect":"Neurotoxicity (tremor, headache, seizures)"},{"rate":null,"effect":"Hyperglycemia / new-onset diabetes"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that prevents T-cell proliferation and cytokine production, providing immunosuppression for transplant rejection prevention. The rapid steroid withdrawal protocol aims to reduce cumulative steroid-related adverse effects (hyperglycemia, hypertension, osteoporosis, infection risk) by transitioning patients off corticosteroids quickly while maintaining tacrolimus-based immunosuppression as the primary agent.","oneSentence":"Tacrolimus suppresses T-cell activation by inhibiting calcineurin, while rapid steroid withdrawal minimizes long-term corticosteroid exposure and associated toxicity in transplant recipients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:53.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention (kidney, heart, liver transplants) with rapid corticosteroid withdrawal protocol"}]},"trialDetails":[{"nctId":"NCT01002339","phase":"PHASE4","title":"Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation","status":"TERMINATED","sponsor":"Armando Torres Ramírez","startDate":"2010-02","conditions":"Diabetes Mellitus, Adult-Onset","enrollment":134},{"nctId":"NCT00596947","phase":"PHASE4","title":"Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2005-10","conditions":"Transplants and Implants","enrollment":18},{"nctId":"NCT00585468","phase":"PHASE4","title":"Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State","status":"COMPLETED","sponsor":"University of Utah","startDate":"2007-12","conditions":"Kidney Transplantation","enrollment":21},{"nctId":"NCT00113269","phase":"PHASE4","title":"Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-05","conditions":"Kidney Transplantation","enrollment":501}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Simulect; Dacortin; Prograf/Advagraf; Cellcept/Myfortic."],"phase":"marketed","status":"active","brandName":"Tacrolimus with rapid steroid withdrawal","genericName":"Tacrolimus with rapid steroid withdrawal","companyName":"Armando Torres Ramírez","companyId":"armando-torres-ram-rez","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus suppresses T-cell activation by inhibiting calcineurin, while rapid steroid withdrawal minimizes long-term corticosteroid exposure and associated toxicity in transplant recipients. Used for Organ transplant rejection prevention (kidney, heart, liver transplants) with rapid corticosteroid withdrawal protocol.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}